Traders Purchase High Volume of Call Options on COMPASS Pathways (NASDAQ:CMPS)

COMPASS Pathways PLC Sponsored ADR (NASDAQ:CMPS) saw some unusual options trading activity on Monday. Investors purchased 5,261 call options on the stock. This is an increase of 420% compared to the typical volume of 1,012 call options.

Institutional Trading of COMPASS Pathways

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Vivo Capital LLC grew its stake in shares of COMPASS Pathways by 109.1% in the first quarter. Vivo Capital LLC now owns 3,362,385 shares of the company’s stock worth $9,616,000 after acquiring an additional 1,754,385 shares during the last quarter. RTW Investments LP acquired a new stake in COMPASS Pathways during the 4th quarter worth $11,714,000. Nantahala Capital Management LLC lifted its stake in shares of COMPASS Pathways by 182.9% in the 1st quarter. Nantahala Capital Management LLC now owns 2,829,232 shares of the company’s stock valued at $8,092,000 after purchasing an additional 1,829,232 shares during the period. ARK Investment Management LLC lifted its stake in COMPASS Pathways by 4.0% in the first quarter. ARK Investment Management LLC now owns 1,804,803 shares of the company’s stock valued at $5,162,000 after buying an additional 68,601 shares during the period. Finally, GMT Capital Corp raised its position in shares of COMPASS Pathways by 15.1% during the first quarter. GMT Capital Corp now owns 1,781,718 shares of the company’s stock worth $5,096,000 after purchasing an additional 233,918 shares during the period. Institutional investors and hedge funds own 46.19% of the company’s stock.

COMPASS Pathways Stock Down 47.6%

CMPS traded down $2.21 during midday trading on Monday, hitting $2.43. 14,633,403 shares of the company’s stock traded hands, compared to its average volume of 991,696. The company has a debt-to-equity ratio of 0.11, a current ratio of 10.18 and a quick ratio of 10.18. The company has a market cap of $226.88 million, a PE ratio of -1.22 and a beta of 2.25. The stock’s fifty day simple moving average is $4.09 and its 200-day simple moving average is $3.89. COMPASS Pathways has a one year low of $2.37 and a one year high of $8.54.

COMPASS Pathways (NASDAQ:CMPS) last posted its quarterly earnings data on Thursday, May 8th. The company reported ($0.44) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.47) by $0.03. As a group, equities analysts anticipate that COMPASS Pathways will post -2.33 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities research analysts have recently issued reports on the stock. Canaccord Genuity Group dropped their price objective on shares of COMPASS Pathways from $23.00 to $15.00 and set a “buy” rating for the company in a research report on Friday, February 28th. Evercore ISI reissued an “in-line” rating and set a $6.00 price target (down previously from $11.00) on shares of COMPASS Pathways in a research report on Monday. Cantor Fitzgerald restated an “overweight” rating and issued a $12.00 price target on shares of COMPASS Pathways in a research report on Tuesday, May 27th. Stifel Nicolaus started coverage on COMPASS Pathways in a report on Thursday, February 27th. They issued a “buy” rating and a $11.00 price target on the stock. Finally, HC Wainwright reaffirmed a “buy” rating and set a $45.00 target price on shares of COMPASS Pathways in a research note on Monday, May 12th. One investment analyst has rated the stock with a hold rating and six have given a buy rating to the company’s stock. According to MarketBeat.com, COMPASS Pathways currently has a consensus rating of “Moderate Buy” and a consensus price target of $17.00.

About COMPASS Pathways

COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa.